RU2237065C2 - Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека - Google Patents

Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека Download PDF

Info

Publication number
RU2237065C2
RU2237065C2 RU2002126396/13A RU2002126396A RU2237065C2 RU 2237065 C2 RU2237065 C2 RU 2237065C2 RU 2002126396/13 A RU2002126396/13 A RU 2002126396/13A RU 2002126396 A RU2002126396 A RU 2002126396A RU 2237065 C2 RU2237065 C2 RU 2237065C2
Authority
RU
Russia
Prior art keywords
hiv
library
chimeric peptides
antibodies
protein
Prior art date
Application number
RU2002126396/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2002126396A (ru
Inventor
А.З. Максютов (RU)
А.З. Максютов
А.А. Колобов (RU)
А.А. Колобов
А.Б. Рыжиков (RU)
А.Б. Рыжиков
А.Н. Канев (RU)
А.Н. Канев
З.А. Максютов (RU)
З.А. Максютов
Original Assignee
Государственный научный центр вирусологии и биотехнологии "Вектор"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственный научный центр вирусологии и биотехнологии "Вектор" filed Critical Государственный научный центр вирусологии и биотехнологии "Вектор"
Priority to RU2002126396/13A priority Critical patent/RU2237065C2/ru
Priority to US10/529,885 priority patent/US20060153865A1/en
Priority to EP03751670A priority patent/EP1558628A4/en
Priority to NZ539606A priority patent/NZ539606A/en
Priority to CA002500401A priority patent/CA2500401A1/en
Priority to PCT/RU2003/000421 priority patent/WO2004031212A1/en
Priority to CNA038255375A priority patent/CN1714100A/zh
Priority to JP2004541361A priority patent/JP2006519160A/ja
Priority to KR1020057005874A priority patent/KR20050067411A/ko
Priority to AU2003269748A priority patent/AU2003269748A1/en
Priority to RU2005108567/04A priority patent/RU2312941C2/ru
Priority to PCT/RU2003/000423 priority patent/WO2004031226A1/ru
Publication of RU2002126396A publication Critical patent/RU2002126396A/ru
Application granted granted Critical
Publication of RU2237065C2 publication Critical patent/RU2237065C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2002126396/13A 2002-10-03 2002-10-03 Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека RU2237065C2 (ru)

Priority Applications (12)

Application Number Priority Date Filing Date Title
RU2002126396/13A RU2237065C2 (ru) 2002-10-03 2002-10-03 Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
US10/529,885 US20060153865A1 (en) 2002-10-03 2003-08-19 Antigenic peptides
NZ539606A NZ539606A (en) 2002-10-03 2003-09-25 Antigenic peptides
CA002500401A CA2500401A1 (en) 2002-10-03 2003-09-25 Antigenic peptides
PCT/RU2003/000421 WO2004031212A1 (en) 2002-10-03 2003-09-25 Antigenic peptides
CNA038255375A CN1714100A (zh) 2002-10-03 2003-09-25 抗原肽
EP03751670A EP1558628A4 (en) 2002-10-03 2003-09-25 ANTIGENIC PEPTIDES
JP2004541361A JP2006519160A (ja) 2002-10-03 2003-09-25 抗原性ペプチド
KR1020057005874A KR20050067411A (ko) 2002-10-03 2003-09-25 항원성 펩티드
AU2003269748A AU2003269748A1 (en) 2002-10-03 2003-09-25 Antigenic peptides
RU2005108567/04A RU2312941C2 (ru) 2002-10-03 2003-09-25 Антигенные пептиды
PCT/RU2003/000423 WO2004031226A1 (fr) 2002-10-03 2003-09-29 Bibliotheque immunogene de peptides chimeriques imitant la diversite genetique de la region hypervariable v3 de la proteine d'enveloppe gp120 du virus de l'immunodeficience humaine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2002126396/13A RU2237065C2 (ru) 2002-10-03 2002-10-03 Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека

Publications (2)

Publication Number Publication Date
RU2002126396A RU2002126396A (ru) 2004-07-20
RU2237065C2 true RU2237065C2 (ru) 2004-09-27

Family

ID=32067104

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002126396/13A RU2237065C2 (ru) 2002-10-03 2002-10-03 Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека

Country Status (10)

Country Link
US (1) US20060153865A1 (cg-RX-API-DMAC7.html)
EP (1) EP1558628A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006519160A (cg-RX-API-DMAC7.html)
KR (1) KR20050067411A (cg-RX-API-DMAC7.html)
CN (1) CN1714100A (cg-RX-API-DMAC7.html)
AU (1) AU2003269748A1 (cg-RX-API-DMAC7.html)
CA (1) CA2500401A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ539606A (cg-RX-API-DMAC7.html)
RU (1) RU2237065C2 (cg-RX-API-DMAC7.html)
WO (2) WO2004031212A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040040A1 (en) * 2011-09-12 2013-03-21 New York University School Of Medicine Peptides mimicking hiv-1 viral epitopes in the v2 loop for the gp120 surface envelope glycoprotein
RU2505604C2 (ru) * 2007-10-09 2014-01-27 Текнолоджи Интеграл Лтд. Профилактическая вакцина против вич, основанная на вич-специфических антителах
RU2603732C2 (ru) * 2011-02-25 2016-11-27 Лабораторьос Дель Др. Эстеве, С.А. Способ быстрого отбора вариантов gp-120 вич

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006227380B2 (en) * 2005-03-17 2012-08-16 Vel Partners Holdings Llc Immunogens for vaccines against antigenically variable pathogens and diseases
WO2007079755A1 (en) 2006-01-12 2007-07-19 Janus Beierholm Holding Aps Reimmunization and antibody design
PL2027158T3 (pl) * 2006-05-02 2013-02-28 Carviar Aps Sposób immunizacji gatunków ptaków
JP2010530356A (ja) * 2007-03-27 2010-09-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 急性伝染hivエンベロープ・サイン
WO2008153925A2 (en) * 2007-06-06 2008-12-18 Danisco Us, Inc., Genencor Division Methods for improving multiple protein properties
BR122020015754B8 (pt) 2008-12-05 2021-04-06 Takeda Vaccines Inc métodos para aumentar a taxa de crescimento viral, para aumentar o tamanho da placa de uma cultura viral, para reduzir o tempo de latência do crescimento de uma cultura viral, e para a cultura de vírus para a produção e fabricação
WO2011138032A2 (en) * 2010-05-05 2011-11-10 Artemev, Timur Universal influenza vaccines and methods for their generation
EP2422618A1 (en) * 2010-08-27 2012-02-29 Technologie Integrale Ltd. Animal model for the evaluation of the efficacy of an HIV vaccine
US10383927B2 (en) 2015-01-09 2019-08-20 Primex Clinical Laboratories, Inc. Variable epitope library compositions and methods of therapeutic and prophylactic use
US12595591B2 (en) 2019-06-27 2026-04-07 Roche Sequencing Solutions, Inc. Peptide libraries having enhanced subsequence diversity and methods for use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042836A (en) * 1993-06-07 2000-03-28 Genentech, Inc. HIV envelope polypeptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0728015B1 (en) * 1992-06-18 2006-03-08 Creagen, Inc. Method of producing a set of combinatorial polypeptide antigens
GB2282378A (en) * 1993-09-30 1995-04-05 Merck & Co Inc Conjugates of epitopes of HIV with a protein complex from Neisseria
EP0725838A4 (en) * 1993-10-26 1997-02-26 United Biomedical Inc STRUCTURED SYNTHETIC ANTIGAN BANKS AS DIAGNOSTICS, VACCINE AND THERAPEUTIC AGENTS
IT1277057B1 (it) * 1995-12-11 1997-11-04 Tecnogen Scpa Peptidi antigenici migliorati
WO2003066090A1 (en) * 2002-02-08 2003-08-14 Variation Biotechnologies Inc. Immunogenic formulations of variable peptidic epitopes and process for preparation thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042836A (en) * 1993-06-07 2000-03-28 Genentech, Inc. HIV envelope polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ESTAQUIER J. et al. The mixotope: a combinatorial library as a T cell and B cell immunogen. Eur. J. Immunol, 1994 Nov.; 24(11):2789-95. CARLOS M.P. et al. Immunogenicity of a vaccine preparation representing the variable regions of the HIV type 1 envelope glycoprotein. AIDS Res. Hum. Retroviruses, 2000 Jan. 20; 16(2):153-61. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2505604C2 (ru) * 2007-10-09 2014-01-27 Текнолоджи Интеграл Лтд. Профилактическая вакцина против вич, основанная на вич-специфических антителах
RU2603732C2 (ru) * 2011-02-25 2016-11-27 Лабораторьос Дель Др. Эстеве, С.А. Способ быстрого отбора вариантов gp-120 вич
WO2013040040A1 (en) * 2011-09-12 2013-03-21 New York University School Of Medicine Peptides mimicking hiv-1 viral epitopes in the v2 loop for the gp120 surface envelope glycoprotein
US9611294B2 (en) 2011-09-12 2017-04-04 New York University Peptides mimicking HIV-1 viral epitopes in the V2 loop for the GP120 surface envelope glycoprotein

Also Published As

Publication number Publication date
CN1714100A (zh) 2005-12-28
EP1558628A4 (en) 2006-05-31
CA2500401A1 (en) 2004-04-15
KR20050067411A (ko) 2005-07-01
WO2004031212A1 (en) 2004-04-15
US20060153865A1 (en) 2006-07-13
NZ539606A (en) 2008-08-29
WO2004031226A1 (fr) 2004-04-15
AU2003269748A1 (en) 2004-04-23
EP1558628A1 (en) 2005-08-03
JP2006519160A (ja) 2006-08-24

Similar Documents

Publication Publication Date Title
US20100121029A1 (en) Anti-hiv immunogenic formulation and process for preparation thereof
EP0328403A2 (en) Synthetic peptides related to the HIV-GP120-env-protein, and their use
US5817318A (en) Synthetic peptides for an HIV-1 vaccine
EP0276279A1 (en) Composition of matter and method of immunizing against viral causative agents of aids and arc
US20060153865A1 (en) Antigenic peptides
AU621317B2 (en) Hiv peptides and methods for detection of hiv
US6210873B1 (en) Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
Xiao et al. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody
JPH083200A (ja) Htlv−iii/lavウイルス関連ペプチドに対する抗体
Anderson et al. Hypervariable epitope constructs as a means of accounting for epitope variability
WO2003059953A2 (en) Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
US7319000B1 (en) Compositions and methods for eliciting immune or anti-infective responses
CA2472265C (en) Immunogenic formulations of variable peptidic epitopes and process for preparation thereof
Iglesias et al. Broader cross-reactivity after conjugation of V3 based multiple antigen peptides to HBsAg
WO2002045743A2 (en) Hcv vaccines
JP2017141291A (ja) ペプチドにおける3個以上のアミノ酸残基の任意に設計されたエピトープを認識する抗体およびその生成方法
NZ235538A (en) Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera
Kanda et al. Dependence of the murine antibody response to an anti-CD4 CDR2 VH peptide on immunogen formulation
CA1293188C (en) Composition of matter and method of immunizing against viral causative agents of aids and arc
Boudet et al. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice
ZA200405492B (en) Immunogenic formulations of variable peptidic epitopes and process for preparation thereof.
Laisney et al. Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1)
HK1058154A1 (en) Method for obtaining antigenic structures enhancing specific cross reactivity
HK1058154B (en) Method for obtaining antigenic structures enhancing specific cross reactivity

Legal Events

Date Code Title Description
PC43 Official registration of the transfer of the exclusive right without contract for inventions

Effective date: 20100419

PD4A Correction of name of patent owner
MM4A The patent is invalid due to non-payment of fees

Effective date: 20141004